Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Corautus Genetics angina drug fails to meet goal
The endpoint in the clinical trial was an improvement of at least one minute in exercise tolerance time from baseline to three months. The data indicated considerable overlap
The endpoint in the clinical trial was an improvement of at least one minute in exercise tolerance time from baseline to three months. The data indicated considerable overlap
The patent is currently due to expire in May 2013 and the decision by the US court could prevent the onset of generic versions of Aciphex. However, the
Symbicort is licensed for use in adults who need an inhaled corticosteroid (ICS) and a long acting bronchodilator (LABA) combination treatment. This new treatment approach enables patients to
Researchers at MIT and Hong Kong University used nanotechnology to develop a liquid which could stop bleeding in animal subjects. When the liquid, composed of protein fragments called
Zolinza is a once daily treatment specifically for patients with cutaneous T-cell lymphoma (CTCL), a form of non-Hodgkin's lymphoma, who have progressive, persistent or recurrent disease on or
The application was filed jointly by the three companies through a newly established three-way joint venture based in Ireland. Discussions among the three companies regarding agreements for manufacturing,
The terms of the settlement, which remain subject to government review, provide that Dr Reddy's may exclusively distribute an authorized generic version of Imitrex in the US. The
The merger consideration, at $37.50 per share in cash, represents a premium of 31% over the trading price of CNS's common stock at close of business on October
According to the agreement, Vaccinex will be eligible to receive milestone payments and royalties and will have the opportunity to participate as a co-development partner in certain markets.
Belerofon has therapeutic potential for the treatment of a number of clinical diseases, including hepatitis C. It is expected that it will be possible to administer the new